(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 5.8MM | - |
Operating Income | -23.1MM | - |
Operating Expenses | 28.9MM | - |
Net Income | -19.6MM | - |
R&D | 10.6MM | +64% |
G&A | 3.6MM | -28% |
Interest Expense | 222K | +5% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
JERSEY CITY, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second-generation fungerp candidate SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, Spain from April 27-30, 2024. SCY-247 is being developed to address sy
SCY-247’s IND-enabling activities continue to advance with initiation of Phase I anticipated in the second half of 2024 Data analysis for the FURI study is ongoing; top line data from the CARES study has been received and is positive and consistent with previously disclosed results from interim analyses The clinical study reports for FURI, CARES and NATURE in refractory invasive fungal infections are on target for delivery to GSK in the first half of 2024 which would trigger a $10 million develo
JERSEY CITY, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced David Angulo, M.D., President and Chief Executive Officer, will present at Guggenheim’s 6th Annual Biotechnology Conference on Wednesday, February 7 at 11:00 A.M. ET. Guggenheim’s 6th Annual Biotechnology Conference Format: Fireside chat and one-on-one meetingsDate: Wed
In vivo data demonstrated response rate for oral SCY-247 similar to current standard of care, intravenous Liposomal Amphotericin B, for the treatment of mucormycosisCombination of SCY-247 and Liposomal Amphotericin B showed significant enhancement in survival and reduction in fungal burden in lung and brain tissue compared to monotherapies JERSEY CITY, N.J., Jan. 29, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and pr
JERSEY CITY, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second generation fungerp candidate SCY-247 for the treatment of mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis (AAAM) Conference in Milan, Italy from January 25 – 27, 2024. Poster Presentati
We're definitely into long term investing, but some companies are simply bad investments over any time frame. It hits...
In this piece, we will take a look at the 11 cheapest stocks with the biggest upside. If you want to skip our introduction to stock valuation and recent market news, then take a look at 5 Cheapest Stocks With Biggest Upside. Identifying the right stocks to invest in is a science that involves evaluating […]
IND enabling development activities for SCY-247, the next generation fungerp from SCYNEXIS’ proprietary antifungal platform, continue to advanceRemediation strategies following the voluntary recall of BREXAFEMME® and the MARIO study clinical hold are being evaluatedWith cash, cash equivalents and investments of $105.2 million as of September 30, 2023, SCYNEXIS projects a cash runway of more than two years JERSEY CITY, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biote
JERSEY CITY, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate, SCY-247, against a broad panel of fungal pathogens. The analyses were presented by Mahmoud Ghannoum, Ph.D, Professor and Director Center for Medical Mycology, Case Western Reserve Universit
JERSEY CITY, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate SCY-247 against a broad panel of fungal pathogens, including echinocandin-resistant Candida and Aspergillus, in an oral presentation at the 11th Congress on Trends in Medical Mycology (TIMM)